Accounts filed on 31-12-2015
Accounts filed on 31-12-2015
trueCambridge Nutraceuticals Limited073223982015-12-31-2446657-184329144605410025020238851074715868826868826446054100250446054100250420504827242204362341096409403168331939721379241721821410582747863785125550175261559116546995797822Basis of accounting
The financial statements have been prepared under the historical cost convention, and in accordance with the Financial Reporting Standard for Smaller Entities (effective January 2015).
Turnover
The turnover shown in the profit and loss account represents amounts invoiced during the year, exclusive of Value Added Tax.
Amortisation
Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over
the useful economic life of that asset as follows:
Intellectual Property - 20 years
Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance
for obsolete and slow moving items.
Operating lease agreements
Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged against profits on a straight line basis over the period of the lease.
Fixed Assets
All fixed assets are initially recorded at cost.
Financial Instruments
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities.
Plant & Machinerystraight line0.3300Fixtures & Fittingsstraight line0.1000Equipmentstraight line0.3300
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
1900019000340924549551327420591121533171081223622322762106111215672635353191Ordinary2023885120238851074715Ordinary1202388510747152023885Ordinary1949170949170949170The company issued 949,170 Ordinary £1 shares at par value during the year.
Share options
Various share options have been granted by the company, as follows:
Date GrantedNo. of SharesExercise Price
19 December 2012170,917£1.00
1 May 20137,000£1.40
16 May 20131,000£2.80
21 September 2015451,182£1.00
Where applicable, conditions attached to the exercising of the options relate to the company's increased product portfolio.
Share options granted to directors
Options granted to 3 directors totalling 295,757 Ordinary shares with a 3 year vesting period.
Options granted to 1 director totalling 90,000 Ordinary shares, vesting in equal tranches over a 3 year period.
Options granted to 1 director totalling 29,833 Ordinary shares with an immediate vesting date.
Other share options granted
Options granted for 41,000 Ordinary shares with a 3 year vesting period.
Options granted for 1,000 Ordinary shares with a 2 year vesting period.
Options granted for 172,509 Ordinary shares with an immediate vesting date.
As part of its license agreement with Cambridge Nutraceuticals Limited dated 19 July 2012, Nestec has the option to acquire 15% of the company's issued ordinary share capital from time to time. At 31 December 2015 the company had issued 2,023,885 ordinary shares. 2016-05-11A R D Cleevelytruetruetruetruexbrli:sharesiso4217:GBPxbrli:pureCambridge Nutraceuticals Limited2015-01-012015-12-31Cambridge Nutraceuticals Limited2014-01-012014-12-31Cambridge Nutraceuticals Limited2013-12-31Cambridge Nutraceuticals Limited2014-12-31Cambridge Nutraceuticals Limited2014-12-31Cambridge Nutraceuticals Limited2015-12-31 2016-09-23
